News | January 28, 2025
RPG Life Sciences posts Q3 FY25 PAT higher at Rs. 34.93 Cr
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
There was no casualty or loss of human life in the incidence
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
RPG Life Sciences has reported total income of Rs. 167.79 crores during the period ended June 30, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
RPG Life Sciences Limited has reported total income of Rs. 155.62 crores during the period ended December 31, 2023
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
Subscribe To Our Newsletter & Stay Updated
